Generic Name: midostaurin

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Novartis

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Rydapt is a kinase inhibitor approved for adults with newly diagnosed acute myeloid leukemia with FLT3 mutations, and for mastocytosis or mast cell leukemia.

General Info

Rydapt inhibits several receptor tyrosine kinases including FLT3, PDGFR, VEGFR and KIT. It interferes with signaling pathways that play a role in cancer cell growth and metabolism. Studies showed that Rydapt plus chemotherapy improved response rates and overall survival compared with chemotherapy alone. It was approved in 2017.


Dosing Info: Rydapt is a capsule taken twice daily with food.

Side Effects

Common side effects include fever, nausea, vomiting, headache, muscle pain, nosebleeds and high blood gucose. Rydapt can cause depletion of white blood cells (neutropenia), which can lead to infections. Potentially serious side effects may include lung problems. Rydapt may cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: November 29, 2018